Analyst Price Targets — TSHA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 6, 2026 3:31 pm | Chris Raymond | Raymond James | $13.00 | $5.27 | StreetInsider | Raymond James on Taysha Gene Therapies (TSHA): 'Continued Regulatory Progress For TSHA-102; Remain Strong Buy Rated' |
| January 5, 2026 12:37 pm | Zachary Fadem | Wells Fargo | $11.00 | $5.25 | TheFly | Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo |
| December 4, 2025 10:14 am | — | Goldman Sachs | $11.00 | $4.49 | TheFly | Taysha Gene Therapies rated Buy versus Early-Stage at Goldman Sachs |
| December 4, 2025 10:08 am | — | UBS | $11.00 | $4.49 | StreetInsider | Goldman Sachs Upgrades Taysha Gene Therapies (TSHA) to Buy |
| November 14, 2025 12:26 pm | Kristen Kluska | Cantor Fitzgerald | $13.00 | $4.06 | StreetInsider | Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA) |
| November 5, 2025 10:53 am | — | JMP Securities | $8.00 | $4.27 | TheFly | Taysha Gene Therapies price target raised to $8 from $6 at Citizens JMP |
| October 2, 2025 5:09 pm | Jack Allen | Robert W. Baird | $12.00 | $4.77 | TheFly | Taysha Gene Therapies price target raised to $12 from $7 at Baird |
| October 2, 2025 3:34 pm | Gil Blum | Needham | $10.00 | $4.77 | TheFly | Needham ups Taysha target on 'derisking' TSHA-102 news |
| August 14, 2024 10:16 am | Keith Tapper | BMO Capital | $5.00 | $2.31 | StreetInsider | BMO Capital Reiterates Outperform Rating on Taysha Gene Therapies (TSHA) |
| July 1, 2024 7:13 am | Christopher Raymond | Piper Sandler | $7.00 | $2.24 | StreetInsider | Taysha Gene Therapies (TSHA) PT Lowered to $7 at Piper Sandler |
Latest News for TSHA
Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) were up 6.9% during mid-day trading on Monday after Canaccord Genuity Group raised their price target on the stock from $14.00 to $17.00. Canaccord Genuity Group currently has a buy rating on the stock. Taysha Gene Therapies traded as high as $4.64 and last
Capricorn Fund Managers Ltd purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ: TSHA) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 300,000 shares of the company's stock, valued at approximately $1,650,000. Capricorn Fund Managers Ltd
DALLAS, April 03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on April 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in…
Taysha Gene Therapies (NASDAQ: TSHA) highlighted clinical, regulatory, and commercial progress for its lead Rett syndrome gene therapy program while also reporting higher operating expenses and a wider net loss for full-year 2025, according to management on the company's March 19 conference call. TSHA-102 development advances with FDA alignment and pivotal trial underway Chief Executive Officer
Taysha Gene Therapies, Inc. (NASDAQ: TSHA - Get Free Report) gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $4.45, but opened at $4.55. Taysha Gene Therapies shares last traded at $4.5150, with a volume of 715,255 shares traded. The company reported ($0.08) earnings per
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TSHA.
U.S. House Trading
No House trades found for TSHA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.